Cureus

Open Access Poster

Cureus

The relationship between hot flashes and testosterone recovery following 12 months of androgen suppression for men with localized prostate cancer in the ascende-rt trial.

Maryam Dosani¹, James Morris², Scott Tyldesley³, Tom Pickles⁴

1. Radiation Oncology, BC Cancer Agency, Vancouver Centre 2. Radiation Oncology, BC Cancer Agency 3. Department of Radiation Oncology, BC Cancer Agency, Vancouver Centre 4. Radiation Oncology, BC Cancer Agency, Vancouver Centre, University of British Columbia

🖂 Corresponding author: Maryam Dosani, maryam.dosani@bccancer.bc.ca

Categories: Radiation Oncology

Keywords: testosterone, prostatic neoplasms, hot flashes, radiation, androgen deprivation therapy, side effects, lhrh agonist, brachytherapy

How to cite this poster

Dosani M, Morris J, Tyldesley S, et al. (2016) The relationship between hot flashes and testosterone recovery following 12 months of androgen suppression for men with localized prostate cancer in the ascende-rt trial.. Cureus 8(9): e.

Abstract

Purpose

This study was designed to characterize the proportion of men who experience hot flashes (flashes), their peak intensity and cessation in relation to testosterone (TT) levels, with androgen deprivation therapy (ADT). These relationships have not been described in the literature previously. We also characterize testosterone recovery following 12 months of ADT in men undergoing external beam radiation therapy (EBRT) (+/- brachytherapy boost).

Materials and methods

This is a pre-specified secondary analysis of the ASCENDE-RT clinical trial, which is a multicenter, randomized trial of dose-escalated EBRT versus low-dose-rate brachytherapy for men with unfavorable-risk localized prostate cancer. 398 men were randomized. All received 12 months of ADT with luteinizing hormone releasing hormone (LHRH) agonist plus a non-steroidal anti-androgen for at least 1 month. TT was measured every two months until 8 months, at one year, every 3 months until 24 months, every 6 months until 5 years, and yearly thereafter. Patients were censored at last follow-up or at date of PSA failure. TT recovery was defined as any single serum TT above threshold, as defined below. Presence and intensity of flashes were assessed every 4 months until 1 year, every 6 months until 5 years, and yearly thereafter.

Results

TT and hot flash data were available in 392 patients. Analysis was restricted to 334 patients in which baseline (pre ADT) TT was collected. Median age at first LHRH injection was 68 years (range 45-86). Median follow-up from date of ADT to last assessment of flashes was 6.1 years.

Median TT at baseline was 13.1 nmol/L. All patients with baseline TT \ge 5 (91% of study cohort) recovered TT to this threshold with a median time to recovery of 9.6 months. 87% of patients

Open Access Published 09/14/2016

Copyright

© Copyright 2016

Dosani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and

reproduction in any medium, provided the original author and source are credited.

Distributed under Creative Commons CC-BY 3.0

Cureus

with baseline TT \ge 7.5 (84% of study cohort) recovered TT to this threshold after a median of 12.7 months. 81% of patients with baseline TT \ge 10 (68% of study cohort), recovered TT to this threshold after a median time of 18.2 months.

94% of men experienced flashes at some point. Flashes were first reported at a median of 4.0 months from first LHRH injection, when the TT had fallen to castrate. Peak intensity of flashes also occurred at this time and TT level. Median time of cessation of flashes was 7.6 months following cessation of ADT, when median TT had risen to 5.7 nmol/L. 91% of patients recover TT to at least this level within a median 10.9 months. At last follow-up, 99.7% of men had cessation of flashes.

Conclusion

Hot flashes occur with castrate levels of testosterone, and cease when TT has recovered to about half the pre-intervention level (5.7nmol/L). Over 90% recover to at least this level.